Skip to content
Frozen copy retrieved 2026-08-20T20:45:00Z for audit 2026-08-20T21-09-12Z. Original URL:
https://www.statnews.com/2026/08/19/mrna-cancer-vaccine-trial-melanoma-merck-moderna/. The Stochastic Parrot does not host or redistribute; this snapshot exists solely so that quoted spans remain verifiable if the original page changes. Character offsets below index into this plain text; highlighted spans are the quotes cited in the audit.
Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
STAT (STAT+ paywalled after first three paragraphs; captured via firecrawl) ·
back to the auditBy Matthew Herper and Angus Chen. VERBATIM (first three paragraphs; rest of article is STAT+ paywall):
- Lead: "A personalized mRNA cancer vaccine, added to an existing treatment, slowed the return of melanoma and its spread to other parts of the body in a late-stage clinical trial, the drugmakers Merck and Moderna announced Wednesday, results that could herald a new, powerful approach in oncology."
- "So-called "neoantigen" vaccines have long been seen as having potential as cancer treatments, but this is the first randomized Phase 3 clinical trial aimed at definitively proving their benefit."
- "If the results hold up — the drugmakers did not immediately release detailed data — they could deliver new hope and potentially longer lives for patients. They could also be a further testament to the power of mRNA as a platform to develop both traditional vaccines and therapeutics."
AUDIT NOTE: Headline uses "succeeded." Dek: "Results could herald a new, powerful approach in other cancers." The third paragraph carries the conditional "If the results hold up" and the disclosure that detailed data were not immediately released. Rest of the body is behind the STAT+ paywall; only these three paragraphs are grounded and fetchable.